CRWEWallStreet.com Stocks In Action on Monday!
Crwewallstreet Newsletter
__ CYTR, CytRx Corporation CYTR announced favorable response and safety indications from a group of patients with advanced solid tumors in the Companys ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
CYTR is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CYTR oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CYTR plans to initiate a Phase 2b clinical trial as a treatment for soft tissue sarcomas in 2011, following its Phase 1b/2 clinical trial. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer. CYTR`s pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled Phase 2 clinical trial in patients with non-small-cell lung cancer, and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL).
More about CYTR at www.cytrx.com ******
SAPX, Seven Arts Entertainment, Inc.
For the fiscal year ended June 30, 2011, Seven Arts Pictures plc, the NASDAQ listing predecessor of SAPX today reported revenue of $3,328,000 and net income of $1,462,000, representing $0.77 of basic and diluted earnings per share.
SAPX is the successor to Seven Arts Pictures Plc, which was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in domestic (i.e., the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.
More about SAPX at www.7artspictures.com ******
PCRX, Pacira Pharmaceuticals, Inc.
PCRX announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration`s approval of EXPAREL and the commercial strategy to support the product launch. Pacira reiterated its revenue expectations for 2011, they currently expect to achieve revenue in the range of $14 to $16 million for the full-year ending December 31, 2011 and this revenue expectation excludes the impact of potential sales of EXPAREL. EXPAREL is an innovative product that combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period.
PCRX is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company`s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL (bupivacaine liposome injectable suspension), was approved for administration into the surgical site to produce postsurgical analgesia by the U.S. Food and Drug Administration in October 2011. EXPAREL and two other commercially available products utilize the PCRX proprietary product delivery technology DepoFoam, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
More about PCRX at www.pacira.com *********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(_Read more at_ http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
— The following information is a reminder of your current mailing list subscription:
You are subscribed to the following list:
Crwewallstreet.com
Related posts:
- Stock-PR.com Stocks In Action on Monday!
- DoubleInStocks.com Stocks In Action on Monday!
- CRWESelect.com Stocks In Action on Monday!
- Top Alert Updates ( PEIX ) ( CYTR ) ( SAPX ) Climbing despite
- Huge Gains & Cancer Stocks ( AEZS ) ( RPC ) ( CYTR )